References

1. Kantarjian H: Chronic myelogenous leukemia: a concise update. Blood 82:691-703, 1993.

2. Faderl S: Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131:207-219, 1996.

3. O'Brien SG: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeleid leukemia. N Engl J Med 348(11): 994-1004, 2003.

4. McGlave PB: Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years experience of the National Marrow Donor Program. Blood 95(7):2219-2225, 2000.

5. Druker BJ: Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038-1042, 2001.

6. Talpaz M: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99(6):1928-1937, 2002.

7. Kantarjian HM: Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8(7):2167-2176, 2002.

8. Kantarjian HM: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99(10):3547-3553, 2002.

tation therapy and plan transplantation prior to disease progression to accelerated and blast phase.

0 0

Post a comment